Clazakizumab
Phase 2Monoclonal antibody
CSL BehringClazakizumab is one of 45 small molecule programs targeting Atherosclerosis. It is currently in Phase 2.
3
Indications
11
Total Trials
3
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
54 competitors in Atherosclerosis
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Niacor
AbbVieApproved
Crestor
AstraZenecaApproved
Praluent
RegeneronApproved
Plavix
SanofiApproved
Aldactone
PfizerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Onglyza
AstraZenecaApproved
Actos
TakedaApproved
Brilinta
AstraZenecaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-194 trials
Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)
Completed·—·Phase 2·NCT04348500·17 enrolled
Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Terminated·—·Phase 2·NCT04381052·1 enrolled
Show 1 more trial
Kidney Transplant2 trials
Inflammation1 trial
Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study
Active, not recruiting·—·Phase 2·NCT05727384·29 enrolled
Asthma1 trial
2 more indications
Renal Transplant1 trial
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Active, not recruiting·—·Phase 1/2·NCT03380962·20 enrolled
Atherosclerosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Clazakizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company